
Raymond J Henley Iii
Examiner (ID: 13341, Phone: (571)272-0575 , Office: P/1629 )
| Most Active Art Unit | 1614 |
| Art Unit(s) | 1205, 1614, 1629, 1621, 2899 |
| Total Applications | 4270 |
| Issued Applications | 3011 |
| Pending Applications | 581 |
| Abandoned Applications | 704 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15381803
[patent_doc_number] => 10532059
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-14
[patent_title] => Steroid hormone pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 15/901467
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 14376
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901467
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/901467 | Steroid hormone pharmaceutical composition | Feb 20, 2018 | Issued |
Array
(
[id] => 15381803
[patent_doc_number] => 10532059
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-14
[patent_title] => Steroid hormone pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 15/901467
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 14376
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901467
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/901467 | Steroid hormone pharmaceutical composition | Feb 20, 2018 | Issued |
Array
(
[id] => 15381803
[patent_doc_number] => 10532059
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-14
[patent_title] => Steroid hormone pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 15/901467
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 14376
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901467
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/901467 | Steroid hormone pharmaceutical composition | Feb 20, 2018 | Issued |
Array
(
[id] => 15381803
[patent_doc_number] => 10532059
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-14
[patent_title] => Steroid hormone pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 15/901467
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 14376
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901467
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/901467 | Steroid hormone pharmaceutical composition | Feb 20, 2018 | Issued |
Array
(
[id] => 12862123
[patent_doc_number] => 20180179215
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-28
[patent_title] => CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 15/901118
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901118
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/901118 | Crystalline forms of a bruton's tyrosine kinase inhibitor | Feb 20, 2018 | Issued |
Array
(
[id] => 12862120
[patent_doc_number] => 20180179214
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-28
[patent_title] => CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 15/900660
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900660
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/900660 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Feb 19, 2018 | Issued |
Array
(
[id] => 15895091
[patent_doc_number] => 20200147064
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor
[patent_app_type] => utility
[patent_app_number] => 16/486616
[patent_app_country] => US
[patent_app_date] => 2018-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486616
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/486616 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | Feb 15, 2018 | Abandoned |
Array
(
[id] => 13885323
[patent_doc_number] => 10195193
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-05
[patent_title] => Levocetirizine and montelukast in the treatment of inflammation mediated conditions
[patent_app_type] => utility
[patent_app_number] => 15/895918
[patent_app_country] => US
[patent_app_date] => 2018-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 25298
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895918
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/895918 | Levocetirizine and montelukast in the treatment of inflammation mediated conditions | Feb 12, 2018 | Issued |
Array
(
[id] => 13276531
[patent_doc_number] => 10149831
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2018-12-11
[patent_title] => Pharmaceutical composition for treating bacterial and viral infections
[patent_app_type] => utility
[patent_app_number] => 15/893199
[patent_app_country] => US
[patent_app_date] => 2018-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2306
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893199
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/893199 | Pharmaceutical composition for treating bacterial and viral infections | Feb 8, 2018 | Issued |
Array
(
[id] => 13325735
[patent_doc_number] => 20180214405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-02
[patent_title] => Methods of Treating Neurodevelopmental Diseases and Disorders
[patent_app_type] => utility
[patent_app_number] => 15/892144
[patent_app_country] => US
[patent_app_date] => 2018-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15892144
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/892144 | Methods of treating neurodevelopmental diseases and disorders | Feb 7, 2018 | Issued |
Array
(
[id] => 14169261
[patent_doc_number] => 10258617
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-16
[patent_title] => Dosing regimens for fast onset of antidepressant effect
[patent_app_type] => utility
[patent_app_number] => 15/890006
[patent_app_country] => US
[patent_app_date] => 2018-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 14547
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890006
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/890006 | Dosing regimens for fast onset of antidepressant effect | Feb 5, 2018 | Issued |
Array
(
[id] => 14357507
[patent_doc_number] => 10300033
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-05-28
[patent_title] => Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
[patent_app_type] => utility
[patent_app_number] => 15/887243
[patent_app_country] => US
[patent_app_date] => 2018-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 73
[patent_no_of_words] => 95568
[patent_no_of_claims] => 56
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15887243
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/887243 | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use | Feb 1, 2018 | Issued |
Array
(
[id] => 12786232
[patent_doc_number] => 20180153913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => STABILIZED LIQUID FOSAPREPITANT FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 15/886247
[patent_app_country] => US
[patent_app_date] => 2018-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6296
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15886247
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/886247 | Stabilized liquid fosaprepitant formulations | Jan 31, 2018 | Issued |
Array
(
[id] => 12785980
[patent_doc_number] => 20180153829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => TREATING ANDROGEN DEPRIVATION THERAPY INDUCED HOT FLASHES AND BONE LOSS IN MEN USING CIS-CLOMIPHENE
[patent_app_type] => utility
[patent_app_number] => 15/879861
[patent_app_country] => US
[patent_app_date] => 2018-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5736
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15879861
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/879861 | Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene | Jan 24, 2018 | Issued |
Array
(
[id] => 13179705
[patent_doc_number] => 10105340
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-10-23
[patent_title] => Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
[patent_app_type] => utility
[patent_app_number] => 15/878827
[patent_app_country] => US
[patent_app_date] => 2018-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14203
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15878827
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/878827 | Composition containing eicosapentaenoic acid alkyl ester, and method for producing same | Jan 23, 2018 | Issued |
Array
(
[id] => 17227150
[patent_doc_number] => 20210353706
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => INHIBITION OF ENDOGENOUS REVERSE TRANSCRIPTASE AND TARGETING OF CELLS FOR PROPHYLAXIS AND THERAPY OF CANCER AND AGING
[patent_app_type] => utility
[patent_app_number] => 16/479809
[patent_app_country] => US
[patent_app_date] => 2018-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8530
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479809
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/479809 | INHIBITION OF ENDOGENOUS REVERSE TRANSCRIPTASE AND TARGETING OF CELLS FOR PROPHYLAXIS AND THERAPY OF CANCER AND AGING | Jan 22, 2018 | Abandoned |
Array
(
[id] => 13049157
[patent_doc_number] => 10045955
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-08-14
[patent_title] => Aqueous gel composition and methods of use
[patent_app_type] => utility
[patent_app_number] => 15/876625
[patent_app_country] => US
[patent_app_date] => 2018-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4402
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876625
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/876625 | Aqueous gel composition and methods of use | Jan 21, 2018 | Issued |
Array
(
[id] => 15114367
[patent_doc_number] => 20190343816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => PHARMACEUTICAL COMPOSITION USED FOR TREATMENT OF HTLV-1-ASSOCIATED MYELOPATHY
[patent_app_type] => utility
[patent_app_number] => 16/477286
[patent_app_country] => US
[patent_app_date] => 2018-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16477286
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/477286 | Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy | Jan 17, 2018 | Issued |
Array
(
[id] => 15144943
[patent_doc_number] => 20190350949
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => PSILOCYBIN AND/OR PSILOCIN IN COMBINATION WITH CANNABINOIDS AND/OR TERPENES
[patent_app_type] => utility
[patent_app_number] => 16/478283
[patent_app_country] => US
[patent_app_date] => 2018-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5666
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16478283
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/478283 | Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes | Jan 17, 2018 | Issued |
Array
(
[id] => 14926199
[patent_doc_number] => 20190298737
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => AN OIL-IN-WATER NANOEMULSION COMPOSITION OF CLOBETASOL
[patent_app_type] => utility
[patent_app_number] => 16/069473
[patent_app_country] => US
[patent_app_date] => 2018-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12780
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16069473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/069473 | Oil-in-water nanoemulsion composition of clobetasol | Jan 17, 2018 | Issued |